Pembrolizumab

Pembrolizumab is a monoclonal antibody used for the treatment of various types of cancer. It is a form of immunotherapy, which harnesses the power of the immune system to fight cancer cells. The medication specifically targets a protein called PD-1, which is found on the surface of certain immune cells called T-cells. By blocking PD-1, Pembrolizumab enhances the ability of T-cells to recognize and attack cancer cells, thus improving the body’s natural defense mechanisms against the disease.
Pembrolizumab has been approved for the treatment of several cancer types, including melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The specific dosage and treatment duration may vary depending on the type and stage of cancer being treated.
Pembrolizumab is administered through intravenous infusion, usually every three weeks. Side effects are common with this medication, but they are typically mild to moderate in severity. Some of the most common side effects include fatigue, muscle or joint pain, skin rash, and gastrointestinal issues such as nausea, diarrhea, or vomiting. In rare cases, more severe side effects may occur, such as inflammation of the lungs or heart, hormone gland problems, or severe allergic reactions.
Before starting treatment with Pembrolizumab, it is important to discuss the potential benefits and risks with a healthcare professional. Regular monitoring during treatment is essential to detect and manage any side effects or complications. While Pembrolizumab can be an effective treatment option for many patients with cancer, it is not suitable for everyone. The decision to use this medication should be made on a case-by-case basis, considering the individual’s specific cancer type, stage, and overall health.